Accelerated PIVOT-006 Timeline and Expanded NMIBC Opportunity Drive CG Oncology Target Hike to $108 and Reinforce Buy Rating

Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on CG Oncology, Inc., boosting the price target to $108.00.

Sam Slutsky has given his Buy rating due to a combination of factors related to CG Oncology’s lead asset and upcoming catalysts. He highlights that the PIVOT-006 Phase 3 trial of cretostimogene as an adjuvant monotherapy for intermediate-risk non-muscle invasive bladder cancer is progressing faster than expected, with topline data now anticipated in the first half of 2026. This study is notable as the first randomized registrational trial in this specific setting, where no approved adjuvant therapies currently exist, and it enrolls a broad, higher-risk intermediate-risk population. Drawing on encouraging prior results in both BCG-naive and BCG-unresponsive high-risk NMIBC, he views the probability of positive PIVOT-006 results as favorable, supported by clinicians’ view that the targeted risk reduction would be clinically meaningful.

Following the trial update, Slutsky incorporates the intermediate-risk NMIBC opportunity directly into his valuation framework for CG Oncology. In doing so, he replaces a more generalized premium for “other indications” with a more explicit contribution from this newly time-bound, late-stage program. This adjustment leads him to raise his price target from $90 to $108 per share, reflecting a higher risk-adjusted value for cretostimogene in this additional setting. He also notes the sizeable addressable U.S. patient population in intermediate-risk NMIBC, which, combined with the accelerated trial timeline and strong physician and patient interest, supports his positive stance on the stock.

In another report released today, JonesTrading also reiterated a Buy rating on the stock with a $85.00 price target.